Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2012; 18(43): 6226-6234
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6226
Figure 2
Figure 2 Effects of erlotinib on the proliferation of pancreatic cancer cell lines. BxPC-3 and Capan-1 cells growing in 96 half-area well plates were starved from serum and treated with different doses of erlotinib for a total of 32 h. DNA synthesis was measured by 5-bromo-2'-deoxyuridine (BrdU) incorporation over the last 8 h. Data represent mean ± SE (n = 6). aP < 0.05 between control cultures without erlotinib.